Quantinuum Inc. Class A Common Stock (QNT) vs Viavi Solutions Inc. (VIAV)
A side-by-side comparison of Quantinuum Inc. Class A Common Stock and Viavi Solutions Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
QNT
Quantinuum Inc. Class A Common Stock
$45.59TechnologyDelayed quote: Oct 6, 2026, 4:00 PM EDT
VIAV
Viavi Solutions Inc.
$48.14TechnologyDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — QNT vs VIAV
growth of $100 · dividends reinvested · last 1yQNT -24.6% (-24.6%/yr)VIAV -11.8% (-11.8%/yr)VIAV compounded faster over this window
QNT VIAV
QNT vs VIAV: by the numbers
- •QNT is the larger company ($12.00B vs $11.88B market cap).
- •Both run net losses; VIAV's is the smaller (-2.00% vs -231.26% net margin).
Metrics side by side
Valuation
| Metric | QNT | VIAV |
|---|---|---|
| Forward P/E | N/A | 29.30 |
| P/S ratio | N/A | 7.82 |
| P/B ratio | 29.06 | 8.20 |
| EV / EBITDA | N/A | 55.89 |
| FCF yield | N/A | 0.70% |
Profitability
| Metric | QNT | VIAV |
|---|---|---|
| Gross margin | 62.16% | 57.66% |
| Operating margin | -1713.66% | 6.92% |
| Net margin | -231.26% | -2.00% |
| ROE | -4.24% | -2.10% |
| ROIC | -29.62% | 2.53% |
Growth (annualized)
| Metric | QNT | VIAV |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 5.37% |
| FCF CAGR (5Y) | N/A | -13.13% |
| Total return CAGR (5Y) | N/A | 24.91% |
Go deeper
Dig into the metrics
Quantinuum Inc. Class A Common Stock ROEViavi Solutions ROEQuantinuum Inc. Class A Common Stock operating marginViavi Solutions operating marginQuantinuum Inc. Class A Common Stock revenue growthViavi Solutions revenue growthQuantinuum Inc. Class A Common Stock free cash flowViavi Solutions free cash flow
Quantinuum Inc. Class A Common Stock & Viavi Solutions appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.